0001104659-22-068079.txt : 20220603 0001104659-22-068079.hdr.sgml : 20220603 20220603160806 ACCESSION NUMBER: 0001104659-22-068079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220601 FILED AS OF DATE: 20220603 DATE AS OF CHANGE: 20220603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHNETTLER THOMAS P CENTRAL INDEX KEY: 0001271857 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40344 FILM NUMBER: 22994412 MAIL ADDRESS: STREET 1: 800 NICOLLET MALL STREET 2: J1012057 CITY: MINNEAPOLIS STATE: MN ZIP: 55402-7020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akoya Biosciences, Inc. CENTRAL INDEX KEY: 0001711933 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 475586242 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 BUSINESS PHONE: 855.896.8401 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 4 1 tm2217652-7_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-06-01 0 0001711933 Akoya Biosciences, Inc. AKYA 0001271857 SCHNETTLER THOMAS P 100 CAMPUS DRIVE,6TH FLOOR MARLBOROUGH MA 01762 1 0 0 0 Common Stock 2813771 I Held by Piper Sandler Merchant Banking Fund II, L.P. Stock Option (Right to Buy 11.24 2022-06-01 4 A 0 30549 0.00 A 2032-06-01 Common Stock 30549 30549 D PSC Capital Management II LLC is the general partner of Piper Sandler Merchant Banking Fund II, L.P. Piper Sandler Companies is the manager of PSC Capital Management II LLC. The reporting person is the Co-CEO of PSC Capital Management II LLC and disclaims beneficial ownership of the shares held by Piper Sandler Merchant Banking Fund II, L.P. Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023 or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. /s/ Thomas P. Schnettler, by Brian McKelligon, as Attorney-in-Fact 2022-06-03